Insulin Resistance News and Research

RSS

Insulin Resistance is a condition in which the body does not respond to insulin properly. This is most common in Type II diabetes or associated with obesity, ketoacidosis, infection, and certain rare conditions. Diminished effectiveness of insulin in lowering blood glucose levels requiring 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

Adiponectin may play a role in development of all-cause dementia and AD in women

A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer disease (AD) in women, according to a study published Online First by the Archives of Neurology, one of the JAMA/Archives journals.

3 Jan 2012

Four or more coffees reduce risk of womb cancer

According to a new study drinking four or more cups of coffee a day may reduce risk of developing endometrial cancer or womb cancer by almost 25 per cent.

1 Jan 2012

Scientists discover missing link between body's biological clock and sugar metabolism system

Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.

20 Dec 2011

Isis announces addition of three new drug development candidates

Isis Pharmaceuticals, Inc. announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.

15 Dec 2011

Liver transplantations for NASH-Cirrhosis increase dramatically

Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes.

15 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Hormone-blocking therapy for prostate cancer doesn't raise the risk of fatal heart attacks - as some recent studies had suggested - according to a new report from Dana-Farber/Brigham and Women's Cancer Center.

7 Dec 2011

Fatty livers burn more fat, not less

When our livers become loaded with fat, it isn't because they are slacking. A new study of human patients in the December Cell Metabolism shows that fatty livers actually burn more fat, not less. All that "hard work" may be at the root of the organ damage that comes with nonalcoholic fatty liver disease (NAFLD), a condition associated with insulin resistance that affects about one in three in the U.S. population.

6 Dec 2011

Combination of metformin and exercise can prevent Type 2 diabetes

Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggests that exercise and one of the most commonly prescribed drugs for diabetes, metformin, each improves insulin resistance when used alone, but when used together, metformin blunted the full effect of a 12-week exercise program in pre-diabetic men and women.

6 Dec 2011

Study identifies ways to differentiate types of diabetes in young Asian Americans

Researchers at Joslin Diabetes Center have determined key differences between Type 1 and Type 2 diabetes in the Asian American population. This study, published today in PLoS ONE, identified ways to differentiate the types of diabetes, which can be clinically similar in young Asian Americans.

6 Dec 2011

Low vitamin D levels may predispose one to type 2 diabetes

A new study shows that people with lower vitamin D levels were more likely to be obese and have higher degrees of insulin resistance, when the hormone becomes less effective at lowering blood sugar.

6 Dec 2011

Low vitamin D levels associated with higher degrees of insulin resistance

A recent study of obese and non-obese children found that low vitamin D levels are significantly more prevalent in obese children and are associated with risk factors for type 2 diabetes. This study was accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

5 Dec 2011

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.

28 Nov 2011

Benefits of vitamin D-fortified yoghurt drink for people with diabetes

People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.

24 Nov 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

EpiGen to collaborate with Nestl- Research Center in Switzerland

The EpiGen Consortium, an international alliance of the world's leading epigenetics researchers (Singapore Institute for Clinical Sciences of the Agency for Science, Technology and Research (A*STAR), National University of Singapore, University of Southampton, Medical Research Council - Lifecourse Epidemiology Unit, AgResearch Limited, Auckland UniServices Limited) are pleased to announce the creation of a research collaboration with Nestl- Research Center in Switzerland.

23 Nov 2011

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

18 Nov 2011

Research into role of insulin in obesity-related cancers

Niyati Parekh, an assistant professor at New York University's Steinhardt School of Culture, Education, and Human Development, has received a $720,000 Research Scholar Grant from the American Cancer Society to study the role of insulin in obesity-related cancers.

17 Nov 2011

Insulin sensitivity in the ovaries and the pituitary linked to infertility

Infertility is common among obese women, but the reasons remain poorly understood and few treatments exist. Now a team of Johns Hopkins Children's Center scientists, conducting experiments in mice, has uncovered what they consider surprising evidence that insulin resistance, long considered a prime suspect, has little to do with infertility in women with type-2 diabetes, polycystic ovary syndrome and metabolic syndrome, all obesity-related conditions.

16 Nov 2011

International consortium develops first-in-class adiponectin receptor agonist

A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium lead by Dr. Eva Surmacz, Associate Professor in Biology (Adjunct) and director of the Obesity and Cancer Program at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology.

16 Nov 2011

Insulin Resistance News and Research

Further Reading

Adiponectin may play a role in development of all-cause dementia and AD in women

Four or more coffees reduce risk of womb cancer

Scientists discover missing link between body's biological clock and sugar metabolism system

Isis announces addition of three new drug development candidates

Liver transplantations for NASH-Cirrhosis increase dramatically

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Fatty livers burn more fat, not less

Combination of metformin and exercise can prevent Type 2 diabetes

Study identifies ways to differentiate types of diabetes in young Asian Americans

Low vitamin D levels may predispose one to type 2 diabetes

Low vitamin D levels associated with higher degrees of insulin resistance

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

Benefits of vitamin D-fortified yoghurt drink for people with diabetes

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

EpiGen to collaborate with Nestl- Research Center in Switzerland

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Research into role of insulin in obesity-related cancers

Insulin sensitivity in the ovaries and the pituitary linked to infertility

International consortium develops first-in-class adiponectin receptor agonist

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News